Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-10 8:34 pm Unchanged |
2024-06-30 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,848,632 12.500% |
0 (Unchanged) |
Filing History |
| 2024-07-10 8:29 pm Sale |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,848,632 17.300% |
-7,965 (-0.21%) |
Filing History |
| 2024-04-15 08:21 am Purchase |
2024-04-11 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
PERCEPTIVE ADVISORS LLC | 5,360,858 17.400% |
2,353,000 (+78.23%) |
Filing History |
| 2024-04-11 4:16 pm Purchase |
2024-04-11 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV |
RA Capital Management, L.P. | 8,359,102 27.100% |
3,541,743 (+73.52%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,649,664 7.400% |
15,515 (+0.95%) |
Filing History |
| 2024-02-14 4:36 pm Unchanged |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
PERCEPTIVE ADVISORS LLC | 3,007,858 13.600% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:51 am Sale |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Marshall Wace North America L.P. | 597,469 2.700% |
-625,783 (-51.16%) |
Filing History |
| 2024-02-13 3:40 pm Sale |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Sands Capital Ventures LLC | 1,652,605 7.400% |
-1 (-0.00%) |
Filing History |
| 2023-03-30 5:07 pm Purchase |
2023-03-28 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV |
RA Capital Management, L.P. | 4,817,359 22.000% |
3,917 (+0.08%) |
Filing History |
| 2023-02-14 3:26 pm Purchase |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Sands Capital Ventures LLC | 1,652,606 7.900% |
1,652,606 (New Position) |
Filing History |
| 2023-02-14 2:33 pm Unchanged |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
PERCEPTIVE ADVISORS LLC | 3,007,858 14.400% |
0 (Unchanged) |
Filing History |
| 2023-02-14 09:35 am Purchase |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Marshall Wace North America L.P. | 1,223,252 5.900% |
1,223,252 (New Position) |
Filing History |
| 2023-02-14 08:02 am Sale |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,634,149 7.800% |
-488 (-0.03%) |
Filing History |
| 2022-11-28 4:31 pm Purchase |
2022-11-17 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV |
RA Capital Management, L.P. | 4,813,442 23.070% |
4,813,442 (New Position) |
Filing History |
| 2022-11-28 3:59 pm Purchase |
2022-11-17 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Chione Ltd. | 3,856,597 18.500% |
3,856,597 (New Position) |
Filing History |
| 2022-11-25 4:25 pm Purchase |
2022-11-15 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Sands Capital Life Sciences Pulse Fund II. L.P. | 1,652,606 7.900% |
1,652,606 (New Position) |
Filing History |
| 2022-11-21 4:01 pm Purchase |
2022-11-09 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,634,637 7.800% |
1,634,637 (New Position) |
Filing History |
| 2022-11-18 4:31 pm Purchase |
2022-11-17 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
PERCEPTIVE ADVISORS LLC | 3,007,858 14.400% |
3,007,858 (New Position) |
Filing History |